Temporary Interruption of Endocrine Therapy for Pregnancy, Including Use of Fertility Preservation, Does Not Increase Risk of Breast Cancer Events in Women with HR-positive Breast Cancer By Ogkologos - July 20, 2026 84 0 Facebook Twitter Google+ Pinterest WhatsApp Updated findings from the POSITIVE study Source RELATED ARTICLESMORE FROM AUTHOR FDA Approves Gedatolisib with Fulvestrant, With or Without Palbociclib, for HR-positive, HER2-negative Locally Advanced or Metastatic Breast Cancer Potential Role of an Activated Tumour Immune Microenvironment in Predicting Benefit from Atezolizumab for TNBC Perioperative Pembrolizumab Plus Neoadjuvant Chemotherapy Continues to Prolong EFS and OS in Patients with Stage II, IIIA, or IIIB (N2) NSCLC MOST POPULAR FDA Grants Accelerated Approval to Pembrolizumab for Locally Recurrent Unresectable or... November 16, 2020 FDA Approves Datopotamab Deruxtecan-dlnk for Unresectable or Metastatic, Hormone Receptor-positive, HER2-negative... February 27, 2025 Altering Diet Enhances Response to Cancer Treatments in Mice September 3, 2019 “Giving something back”: our supporters are the beating heart of what... August 17, 2022 Load more HOT NEWS Immune Checkpoint Inhibitor-Based Systemic Therapy Combinations for Patients with HCC Amenable... EMA Recommends Refusal of the Marketing Authorisation for Tagraxofusp Cómo mantenerse seguro e independiente durante el tratamiento contra el cáncer Tumor Signatures May Help Explain Global Differences in Kidney Cancer Rates
